An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Bicycle Therapeutics (NASDAQ: BCYC) will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 8:45 a.m. ET. The event will be available via a live webcast on Bicycle's website, with an archived replay accessible for 90 days post-event. Bicycle Therapeutics specializes in pioneering therapeutics using its proprietary Bicycle technology, focusing on clinical-stage biopharmaceuticals that target underserved diseases. Current development includes BT5528, BT8009, BT7480, and BT1718 across various trials.
Positive
None.
Negative
None.
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 8:45 a.m. ET.
A live webcast of the fireside chat will be accessible in the Investors and Media section of Bicycle’s Website at www.bicycletherapeutics.com. An archived replay of the webcast will be available for 90 days following the fireside chat date.
About Bicycle Therapeutics
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.
When is the Bicycle Therapeutics fireside chat at the Needham Virtual Healthcare Conference?
Bicycle Therapeutics will participate in the fireside chat on April 13, 2022, at 8:45 a.m. ET.
How can I access the Bicycle Therapeutics fireside chat?
The fireside chat will be accessible via a live webcast on Bicycle Therapeutics' website, with an archived replay available for 90 days.
What is the focus of Bicycle Therapeutics' research and development?
Bicycle Therapeutics focuses on developing a new class of therapeutics using its Bicycle technology, targeting diseases that are underserved by current treatments.
What products is Bicycle Therapeutics currently developing?
Bicycle Therapeutics is currently developing BT5528, BT8009, BT7480, and BT1718, which are in various clinical trials.
Bicycle Therapeutics plc American Depositary Shares
